MTOR and breast cancer: In breast cancer cells, CD82 inhibits ligand-induced dimerization of EGFR, attenuating the downstream signalling pathways of mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription protein (STAT), and mammalian target of rapamycin (mTOR) that leads to cell proliferation and survival [29, 32].